

Appl. No. 09/922,549
 Reply to Office action of July 27, 2005

Amendments to the Specification :

Please replace the paragraph beginning at page 29, line 5, with the following rewritten paragraph:

--Other preferred transfecting agents include but are not limited to ~~lipofectamine~~, ~~lipfectamine~~, LIPOFECTAMINE™ (i.e., DOSPA N-D2-({2,5-bis[(3-aminopropyl)amino]-1-oxy-pentyl}amino)ethyl]-N,N-dimethyl-1-2,3-bis(9-octadecenyloxy)-1-propanaminium trifluoroacetate), DIMRIE C™, Supfect, SUPERFECT®, and Effectin, EFFECTENE™ (Qiagen), ~~unifectin~~, UNIFECTIN™, ~~maxifectin~~, MAXIFECTIN™, LIPOFECTIN® (i.e., DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride)), DOGS (Transfectam; dioctadecylamidoglycylspermine), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), DOTAP (1,2-dioleoyl-3-trimethylammonium propane), DDAB (dimethyl dioctadecylammonium bromide), DHDEAB (N,N-di-n-hexadecyl-N,N-dihydroxyethyl ammonium bromide), HDEAB (N-n-hexadecylN,N-dihydroxyethylammonium bromide), polybrene, or poly(ethylenimine) (PEI). These non-viral agents have the advantage that they can facilitate stable integration of xenogeneic DNA sequences into the vertebrate genome, without size restrictions commonly associated with virus-derived transfecting agents.--